278 Chapter 11 73. Norcross MA, Luo S, Lu L, Boyne MT, Gomarteli M, Rennels AD, et al. Abacavir induces loading of novel self-peptides into HLA-B*57: 01: an autoimmune model for HLA-associated drug hypersensitivity. AIDS. 2012;26(11):F21-9. 74. Venet F, Filipe-Santos O, Lepape A, Malcus C, Poitevin-Later F, Grives A, et al. Decreased T-cell repertoire diversity in sepsis: a preliminary study. Critical care medicine. 2013;41(1):111-9. 75. DiGiandomenico A, Keller AE, Gao C, Rainey GJ, Warrener P, Camara MM, et al. A multifunctional bispecific antibody protects against Pseudomonas aeruginosa. Science translational medicine. 2014;6(262):262ra155. 76. Opal SM. Non-antibiotic treatments for bacterial diseases in an era of progressive antibiotic resistance. Critical care (London, England). 2016;20(1):397. 77. Reardon S. Phage therapy gets revitalized. Nature. 2014;510(7503):15-6. 78. Mai GT, McCormack JG, Seow WK, Pier GB, Jackson LA, Thong YH. Inhibition of adherence of mucoid Pseudomonas aeruginosa by alginase, specific monoclonal antibodies, and antibiotics. Infect Immun. 1993;61(10):4338-43. 79. Badarau A, Trstenjak N, Nagy E. Structure and Function of the Two-Component Cytotoxins of Staphylococcus aureus - Learnings for Designing Novel Therapeutics. Adv Exp Med Biol. 2017. 80. Fischetti VA. Bacteriophage endolysins: a novel anti-infective to control Gram-positive pathogens. Int J Med Microbiol. 2010;300(6):357-62. 81. Hockstein NG, Thaler ER, Torigian D, Miller WT, Jr., Deffenderfer O, Hanson CW. Diagnosis of pneumonia with an electronic nose: correlation of vapor signature with chest computed tomography scan findings. Laryngoscope. 2004;114(10):1701-5. 82. Vincent JL, Brealey D, Libert N, Abidi NE, O’Dwyer M, Zacharowski K, et al. Rapid Diagnosis of Infection in the Critically Ill, a Multicenter Study of Molecular Detection in Bloodstream Infections, Pneumonia, and Sterile Site Infections. Critical care medicine. 2015;43(11):228391. 83. Seymour CW, Gomez H, Chang CH, Clermont G, Kellum JA, Kennedy J, et al. Precision medicine for all? Challenges and opportunities for a precision medicine approach to critical illness. Critical care (London, England). 2017;21(1):257. 84. Netea MG, Balkwill F, Chonchol M, Cominelli F, Donath MY, Giamarellos-Bourboulis EJ, et al. A guiding map for inflammation. Nat Immunol. 2017;18(8):826-31. 85. Adib-Conquy M, Cavaillon JM. Compensatory anti-inflammatory response syndrome. Thromb Haemost. 2009;101(1):36-47. 86. Beutler B, Milsark IW, Cerami AC. Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin. Science, 1985, 229(4716):869-871. Classical article. J Immunol. 2008;181(1):7-9. 87. Beutler B, Cerami A. The biology of cachectin/TNF--a primary mediator of the host response. Annu Rev Immunol. 1989;7:625-55. 88. Boomer JS, To K, Chang KC, Takasu O, Osborne DF, Walton AH, et al. Immunosuppression in patients who die of sepsis and multiple organ failure. Jama. 2011;306(23):2594-605. 89. Leentjens J, Kox M, van der Hoeven JG, Netea MG, Pickkers P. Immunotherapy for the adjunctive treatment of sepsis: from immunosuppression to immunostimulation. Time for a paradigm change? American journal of respiratory and critical care medicine. 2013;187(12):1287-93. 90. Chan JK, Roth J, Oppenheim JJ, Tracey KJ, Vogl T, Feldmann M, et al. Alarmins: awaiting a clinical response. The Journal of clinical investigation. 2012;122(8):2711-9.
RkJQdWJsaXNoZXIy MTk4NDMw